
October 01, 2024
Hydration solutions company The Hydration Pharmaceuticals Company Limited (ASX: HPC) (“Hydralyte US” or “the Company”) refers to its announcement released pre-open on 2 October 2024 regarding entry into an Intellectual Property Sales Agreement (the ‘Agreement’) and related documents with Prestige Consumer Healthcare Inc. and associated subsidiaries.
Hydralyte US is pleased to announce that the Agreement has completed and the sale proceeds of approximately US$9.45m (A$13.7m) have been received.
Click here for the full ASX Release
This article includes content from The Hydration Pharmaceuticals Company Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
HPC:AU
The Conversation (0)
30 May 2024
Hydralyte International
Leveraging a Rapidly Expanding Hydration Market in North America
28 February
FY24 Appendix 4E
Hydralyte International (HPC:AU) has announced FY24 Appendix 4EDownload the PDF here. Keep Reading...
31 January
Q4 FY24 Quarterly Activities Report (App 4C)
Hydralyte International (HPC:AU) has announced Q4 FY24 Quarterly Activities Report (App 4C)Download the PDF here. Keep Reading...
28 November 2024
US Operations Update
Hydralyte International (HPC:AU) has announced US Operations UpdateDownload the PDF here. Keep Reading...
Latest News
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00